Fortis Healthcare share price hits 52-week high; Goldman Sachs maintains buy'
The share price has risen more than 90 percent in the last year17-08-2021
17-08-2021
Fortis Healthcare reports Q1 net profit of Rs 431 cr on one-off gain
The company had posted a consolidated net loss of Rs 187.88 crore in the same quarter last fiscal, Fortis Healthcare said in a regulatory filing14-08-2021
Q1FY22 Result Announced for Fortis Healthcare Ltd.
Fortis Healthcare reports Q1 FY 22 Financial Results: Strong rebound in Hospitals and Diagnostics as impact of Covid abates SRL completes acquisition of balance 50% stake in DDRC JV, making it a 100% subsidiary Acquisition enables SRL to consolidate its position as the 2nd largest diagnostics chain pan – India. Revenues for Q1FY22 at INR 1,410 Crs vs INR 606 Crs in Q1FY21 EBITDA at INR 283 Crs versus a loss of INR 99 Crs in Q1FY21 PAT at INR 431 Crs versus a loss of INR 188 Crs in Q1FY21 Consolidated Financial Snapshot: Q1FY22 hospital business revenues were at INR 1,006.5 Crs versus INR 488.4 Crs in Q1FY21 and INR 982.2 Crs in Q4FY21. The hospital business EBITDA was at INR 149.6 Crs versus a loss of INR 85 Crs in Q1FY21. EBITDA in Q4 FY21 stood at 139.4 Crs. (14.9% margin in Q1 FY22 versus 14.2% in Q4 FY21) SRL registered the highest growth in revenues in the diagnostics space. Q1 FY22 diagnostics business gross revenues grew 214% YoY to INR 441.4 Crs versus INR 140.4 Crs in Q1FY21. Revenues were up 44% versus Q4FY21. The diagnostics business EBITDA was at INR 134.9 Crs versus a loss of INR 10.6 Crs in Q1 FY21. EBITDA in Q4 FY21 stood at INR 67.2 Crs. (30.6% margin in Q1 FY22 versus 22.0% margin in Q4 FY21) Net debt to EBITDA was at 0.90x versus 1.04x in Q4 FY21. Net debt was at INR 1,014 Crs versus INR 849 Crs in Q4 FY21. Commenting on the results for the quarter, Dr Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “Our efforts and the resilience of our workforce has enabled us to respond to the second wave as effectively as possible and simultaneously ensure that our core business remains on track. Month on month non covid occupancy improved from 30% in May to approx. 47% in June. We expect the momentum to continue allowing the business to return to near normal in the short term. We are also progressing well on our strategic initiatives and have also initiated investments for advanced medical equipment such as Cath Labs, neuro microscopes, bone marrow transplant units and the likes in select facilities. The diagnostics business I believe is now well positioned for accelerating its growth and profitability. At the same time, we cannot discount the possibility of a third wave which could impact operations in future. However, having augmented our resources both on the clinical and non-clinical fronts, we are relatively better prepared for such eventualities. FY22 has seen a challenging start but business has recovered well and I expect to see progressively better quarters going forward.” Result PDF13-08-2021
FORTIS HEALTHCARE LTD. - 532843 - Un-Audited Financial Results For Quarter Ended June 30, 2021 Alongwith Press Release And Investors Presentation.
Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. August 13, 2021, inter-alia, considered and approved standalone and consolidated un-audited financial results of the Company for the period ended on June 30, 2021 along with limited review report thereon. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for period ended on June 30, 2021. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed. The meeting commenced at 1100 Hours IST and concluded at 1740 Hours IST. This is for your information and records please.13-08-2021
FORTIS HEALTHCARE LTD. - 532843 - Board Meeting Outcome for Outcome Of The Board Meeting And Disclosure Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. August 13, 2021, inter-alia, considered and approved standalone and consolidated un-audited financial results of the Company for the period ended on June 30, 2021 along with limited review report thereon. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for period ended on June 30, 2021. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed. The meeting commenced at 1100 Hours IST and concluded at 1740 Hours IST. This is for your information and records please.13-08-2021
FORTIS HEALTHCARE LTD. - 532843 - Board Meeting Intimation for Notice Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday, August 13, 2021 to, inter-alia, consider and approve un-audited financial results for the quarter ended June 30, 2021. Further, in continuation to our letter ref. FHL/SEC/2021-22 dated June 29, 2021 captioned 'Closure of Trading Window', it is hereby informed that the trading window of the Company for dealing in securities of the Company will remain closed till August 15, 2021. This is for your information and record please.06-08-2021
FORTIS HEALTHCARE LTD. - 532843 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Please find enclosed the voting results of the 25th Annual General Meeting held on July 30, 2021 at 2:00 P.M. (IST) in the prescribed format along with consolidated Scrutinizer's Report. This is for your information and records please.31-07-2021
FORTIS HEALTHCARE LTD. - 532843 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Fortis Healthcare Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here31-07-2021
Fortis Healthcare Ltd - 532843 - Shareholder Meeting / Postal Ballot-Outcome of AGM
It is hereby informed that 25th Annual General Meeting ('AGM') of the Members of Fortis Healthcare Limited ('the Company') was held on Friday, July 30, 2021 at 2:00 P.M. (IST) through Video Conferencing/ Other Audio Visual Means (VC/OAVM) in compliance with the circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India.30-07-2021
Fortis Healthcare (254.8): Buy
Investors with a short-term horizon can buy the stock of Fortis Healthcare at current levels. The stock has been in an intermediate-term uptrend since28-07-2021